Search - tctmd.com

Displaying 41 - 60 of 78

Sort: Relevancy | Date

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Conference News EuroPCR 2022

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

Michael O'Riordan

May 19, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Opinion CV Team Dispatch

April 2022 News Roundup

L.A. McKeown

April 01, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Daily News

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

Todd Neale

October 20, 2021

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Todd Neale

September 13, 2021

News Daily News

Making the Case for Sex-Specific CVD Guidelines

L.A. McKeown

July 08, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

News Opinion CV Team Dispatch

June 2021 News Roundup

L.A. McKeown

June 01, 2021

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Advertisement

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

What’s Going to Be Hot at ESC 2022?

Dapagliflozin Boosts Health Status Across LVEF Range

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 2022 News Roundup

FDA Approves Empagliflozin for Treatment of HFpEF

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Canagliflozin Improves Quality of Life in HF Patients

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Making the Case for Sex-Specific CVD Guidelines

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

June 2021 News Roundup

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content